BLOOD, WHOLE

Esophageal Cancer

Paradigm Healthother_biologicalActive

D

28/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 65/ 100

Competitive context

130 Active assets in the Esophageal Cancer cohort.

Asset / Sponsor	Phase	Rating
Tisotumab Vedotin Seagen Inc.	Phase 2	BB
FLUOROURACILUM Merck Sharp & Dohme LLC	Phase 4	BB
Benadryl Ciusss de L'Est de l'Île de Montréal	Phase 3	B
Cyclophosphamide Sutro Biopharma, Inc.	Phase 3	B
Epirubicin Sutro Biopharma, Inc.	Phase 3	B

View all 50 →

Same molecule, other indications

BLOOD, WHOLE is also rated in:

hepatic encephalopathyDormant

BB

Indicative ·

64 / 100

cirrhosis of liverDormant

B

Indicative ·

61 / 100

Shock HypovolemicDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.